L’intesa prevede il lancio di un’offerta pubblica di acquisto su tutte le azioni in circolazione della società americana al prezzo di 124 dollari per azione in contanti

The deal comes at a time of biotech dealmaking frenzy, driven by looming patent cliffs, newly buoyant public markets and drugmakers' race to bolster pipelines.

GSK serait en discussions avancées pour racheter la biotech Nuvalent pour 9 à 10 milliards de dollars, selon le Financial Times. L’opération, qui pourrait être conclue dès cette…

GSK is in negotiations to acquire cancer biotech Nuvalent for over $9 billion amid a surge in biotech mergers.

The acquisition is thought to be GSK’s biggest deal in more than a decade.

Operazione da 10,6 mld di dollari con il lancio di un'Opa